Immix Biopharma announced positive interim results from its fully enrolled, 45-patient Phase 2 NEXICART-2 clinical trial for its CAR-T therapy, NXC-201, in patients with relapsed/refractory AL Amyloidosis. The update highlights a high rate of efficacy and a favorable safety profile for the treatment.
Key Details
- Efficacy Data: Across all 45 patients, NXC-201 achieved an 89% (40/45) complete response (CR) rate. The CR rate could potentially increase to 98% (44/45), as patients who are Minimum Residual Disease (MRD)-negative have historically converted to CR within one year.
- Safety & Durability: No relapses have been observed to date in patients achieving CR or MRD-negativity. Additionally, no neurotoxicity or enterocolitis has been reported.
- Next Steps: The company plans for the final trial readout and subsequent Biologics License Application (BLA) submission in mid-2027.